September 2013
Table of Contents
|
Shared Resource Spotlight
Patient/Community-Centered Outcomes Core
Massey recently developed a new shared resource core, Patient/Community-Centered Outcomes Core (PC-COC).
This developing core has the following specific aims: facilitate inter-programmatic research that incorporates patient/community-centered outcomes; promote the inclusion of patient/community-centered outcomes during the pre-award developmental phase of studies, especially clinical trials; and assist Massey investigators in incorporating patient/community-centered outcomes via state-of-the-art qualitative, quantitative and multi-method research protocols.
|
|
 |
|
Leaders' Update 
A message from Mary Ann Hager, R.N., M.S., associate director for clinical services
Massey's clinical services are growing and expanding on several fronts.
This message continues with updates about Massey's:
|
Research Highlights
|
 Making strides against breast cancer
In honor of National Breast Cancer Awareness Month, below is a sampling of the latest advances in breast cancer that Massey is making and current research that we're conducting:
|
Bacterial cells in the gut found to produce steroid hormones that could have implications for prostate and colon cancer
Researchers used advanced technology to identify genes of a bacterium that is found in the gut and involved in the production of androgens, which may play a role in prostate and colon cancer.
|
Center News
|
Massey introduces new, high-tech radiation technology to improve cancer care
Massey has made a significant investment in improving the region's cancer care by becoming the only cancer care provider in Richmond to utilize the TrueBeam™ linear accelerator. This advanced machine, made by Varian Medical Systems, incorporates the latest image-guided radiation therapy technologies and higher dose rates to more accurately target patients' tumors while sparing healthy tissue, reducing side effects and decreasing treatment times.
|
Member Showcase
 |
Cancer Cell Signaling and Cancer Molecular Genetics
member |
New chair of pathology joins Massey
Massey welcomes Charles Clevenger, M.D., Ph.D., as a new member of the Cancer Cell Signaling and Cancer Molecular Genetics programs. He studies the role that the neuroendocrine hormone prolactin plays during the pathogenesis of breast cancer.
Clevenger was recently appointed the chair of the Department of Pathology and has an R01 from the NIH studying the multimeric signaling complexes in PRLr transduction.
|
Researcher Recognition
|
Massey researchers receive $18.1 million grant to lead public health study on tobacco
 | |
Cancer Prevention and Control
members
|
Cancer prevention and control members Thomas Eissenberg, Ph.D., and Robert Balster, Ph.D., recently received an $18.1 million federal grant--VCU's third largest to date--to study modified risk tobacco products and other novel tobacco products, such as electronic cigarettes, and to develop an evaluation tool to help inform United States tobacco regulatory policy.
The multi-year grant will involve four components: examination of factors that influence MRTP nicotine and toxicant yield; comparison of short-term effects of MRTP to other products; a randomized control trial; and MRTP use and misuse on user's attitudes, beliefs and perceived effects.
|
|
|
|
|
|
|
Upcoming Events
Note: 12-1 p.m. time for this seminar only. New seminar time is 4:30 to 5:30 p.m.
Fundraising Event
For a full listing of events,
|
Massey in the Media
Richmond Times-Dispatch
ABC WRIC-TV8
Press coverage is compiled monthly for your convenience.
|
The Wall Street Journal
|
|
|
|
|
Share with us your research, awards and accomplishments!
|
|
Connect with us!
Join Massey's online communities.
|
|
|
|
